loader
Please Wait
Applying Filters...

EuroAPI Header EuroAPI Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Technical details about Acipimox, learn more about the structure, uses, toxicity, action, side effects and more

    Client Email Product
    Menu

    Acipimox

    APIs // Active Pharmaceutical Ingredients

    DOSSIERs // Finished Dosage Forms

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass

    With Fermion, start the journey of your innovative API.

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

    2D Structure
    1. Also known as: 51037-30-0, Olbetam, 5-carboxy-2-methylpyrazine 1-oxide, Olbemox, 5-methylpyrazine-2-carboxylic acid 4-oxide, 5-methylpyrazinecarboxylic acid 4-oxide
    Molecular Formula
    C6H6N2O3
    Molecular Weight
    154.12  g/mol
    InChI Key
    DJQOOSBJCLSSEY-UHFFFAOYSA-N
    FDA UNII
    K9AY9IR2SD
    Acipimox is a niacin derivative and nicotinic acid analog with activity as a hypolipidemic agent. Acipimox has special application for the treatment of hyperlipidemia in non-insulin-dependent diabetic patients.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    5-methyl-4-oxidopyrazin-4-ium-2-carboxylic acid
    2.1.2 InChI
    InChI=1S/C6H6N2O3/c1-4-2-7-5(6(9)10)3-8(4)11/h2-3H,1H3,(H,9,10)
    2.1.3 InChI Key
    DJQOOSBJCLSSEY-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    CC1=CN=C(C=[N+]1[O-])C(=O)O
    2.2 Other Identifiers
    2.2.1 UNII
    K9AY9IR2SD
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 5-methylpyrazine-2-carboxylic Acid 4-oxide

    2. 5-methylpyrazinecarboxylic Acid 4-oxide

    3. Nedios

    4. Olbemox

    5. Olbetam

    2.3.2 Depositor-Supplied Synonyms

    1. 51037-30-0

    2. Olbetam

    3. 5-carboxy-2-methylpyrazine 1-oxide

    4. Olbemox

    5. 5-methylpyrazine-2-carboxylic Acid 4-oxide

    6. 5-methylpyrazinecarboxylic Acid 4-oxide

    7. 5-methyl-4-oxidopyrazin-4-ium-2-carboxylic Acid

    8. 2-carboxy-5-methylpyrazine 4-oxide

    9. K-9321

    10. Nsc-759818

    11. Chembl345714

    12. Ncgc00160519-01

    13. Dsstox_cid_26202

    14. Dsstox_rid_81433

    15. 5-methyl-4-oxido-2-pyrazin-4-iumcarboxylic Acid

    16. Dsstox_gsid_46202

    17. Cas-51037-30-0

    18. Sr-05000001505

    19. 5-methyl-2-pyrazinecarboxylic Acid 4-oxide

    20. Acipimox-[d4]

    21. Mfcd00865757

    22. Acipimox (inn/ban)

    23. Acipimox [inn]

    24. Acipimox [mi]

    25. Pyrazinecarboxylic Acid, 5-methyl-, 4-oxide

    26. Acipimox [mart.]

    27. K9ay9ir2sd

    28. Acipimox [who-dd]

    29. Schembl48922

    30. Gtpl1596

    31. Dtxsid2046202

    32. Chebi:94688

    33. Hms2090g05

    34. Hms3655a14

    35. Hms3713l18

    36. Pharmakon1600-01504831

    37. 5-carboxy-2-methylpyrazine1-oxide

    38. Bcp28412

    39. Hy-b0283

    40. Zinc1481960

    41. Tox21_111868

    42. Tox21_112498

    43. Tox21_112805

    44. Ac-009

    45. Bbl009924

    46. Bdbm50208130

    47. Nsc759818

    48. S1806

    49. Stk711089

    50. 2-carboxy-5-methyl-pyrazine-4-oxide

    51. Akos005530658

    52. Ccg-213957

    53. Db09055

    54. Mb01535

    55. 4-oxo-5-methyl-2-pyrazinecarboxylicacid

    56. Ncgc00160519-02

    57. Ncgc00160519-03

    58. As-15565

    59. Ba166874

    60. 5-methyl-4-oxy-pyrazine-2-carboxylic Acid

    61. Ft-0601589

    62. M2053

    63. Sw199084-2

    64. D07190

    65. Ab01274727-01

    66. Ab01274727-02

    67. Ab01274727_03

    68. Ab01274727_04

    69. K-9321;olbemox;olbetam; K9321; K 9321

    70. A828409

    71. 5-methyl-4-oxide-2-pyrazinecarboxylic Acid

    72. 5-methylpyrazine-2-carboxylic Acid-4-oxide

    73. Q2342544

    74. Sr-05000001505-1

    75. Sr-05000001505-2

    76. W-105921

    77. Brd-k63736853-001-01-4

    2.4 Create Date
    2005-12-16
    3 Chemical and Physical Properties
    Molecular Weight 154.12 g/mol
    Molecular Formula C6H6N2O3
    XLogP3-1
    Hydrogen Bond Donor Count1
    Hydrogen Bond Acceptor Count4
    Rotatable Bond Count1
    Exact Mass154.03784206 g/mol
    Monoisotopic Mass154.03784206 g/mol
    Topological Polar Surface Area75.6 Ų
    Heavy Atom Count11
    Formal Charge0
    Complexity162
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    Used in the treatment of hyperlipidemias (abnormally elevated levels of any or all lipids and/or lipoproteins in the blood).

    5 Pharmacology and Biochemistry
    5.1 MeSH Pharmacological Classification

    Hypolipidemic Agents

    Substances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS. (See all compounds classified as Hypolipidemic Agents.)

    5.2 ATC Code

    C10AD06

    S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355

    C - Cardiovascular system

    C10 - Lipid modifying agents

    C10A - Lipid modifying agents, plain

    C10AD - Nicotinic acid and derivatives

    C10AD06 - Acipimox

    5.3 Mechanism of Action

    Acipimox inhibits the production of triglycerides by the liver and the secretion of VLDL, which leads indirectly to a modest reduction in LDL and increase in HDL.

    Post Enquiry
    POST ENQUIRY